<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04328298</url>
  </required_header>
  <id_info>
    <org_study_id>DESCAR-T</org_study_id>
    <nct_id>NCT04328298</nct_id>
  </id_info>
  <brief_title>French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment</brief_title>
  <official_title>French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Lymphoma Academic Research Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Lymphoma Academic Research Organisation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a registry including prospective and retrospective data on all patients who
      have been presented in a Multidisciplinary tumor board or RCP to be eligible for CAR-T cell
      treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 19, 2019</start_date>
  <completion_date type="Anticipated">December 19, 2038</completion_date>
  <primary_completion_date type="Anticipated">December 19, 2038</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>15 Years</target_duration>
  <primary_outcome>
    <measure>overall survival from eligibility</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival from administration</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of response</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Delays between patient eligibility and CAR-T treatment</measure>
    <time_frame>15 years</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Hematopathology Eligible or CAR-t Cell Treatment</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patient eligible for a treatment with CAR-T for an hematological malignancy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Retrospective inclusion :

          -  Patient treated with CAR-T from 1 July 2018 under temporary authorization (ATU) or
             covered by French health insurance system (under post-ATU or MA) in a qualified center
             before activation of this register in this center

          -  If the patient is alive, the patient has been informed of the collection and use of
             their data, and the patient has not opposed this use. If the patient has died, the
             patient did not opposed the use of their data while alive

        Prospective inclusion :

          -  Patient eligible for a treatment with CAR-T for an hematological malignancy which is
             covered by French health insurance (for ATUs / post-ATUs or MA), or as part of a
             clinical trial with the same indication, after the activation of this register in this
             center.

          -  Patient whose CAR-T indication has been validated during a multidisciplinary tumor
             board (RCP) of a qualified center, according to the ministerial order of 8 August 2019

          -  Patient deemed eligible for a treatment with CAR-T after a medical exam performed in a
             qualified center according to the ministerial order of 8 August 2019

          -  If the patient is alive, the patient has been informed of the collection and use of
             their data, and the patient has not opposed this use. If the patient has died, the
             patient did not opposed the use of their data while alive.

        Exclusion Criteria Patient not registered with the social security in France
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>CHU d'Estaing</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Romain Guieze, MD</last_name>
      <phone>+33 (0)4 73 75 00 65</phone>
      <email>rguieze@chu-clermontferrand.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hopital Henri Mondor</name>
      <address>
        <city>Creteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corinne HAIOUN, MD</last_name>
      <phone>+33 (0)1 49 81 21 11</phone>
      <email>corinne.haioun@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier CASASNOVAS, Pr</last_name>
      <phone>+33 (0)3 80 29 50 41</phone>
      <email>olivier.casasnovas@chu-dijon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille - Hôpital Claude Hurriez</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franck MORSCHHAUSER, Pr</last_name>
      <phone>+33 (0)3 20 44 57 13</phone>
      <email>franck.morschhauser@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reda BOUABDALLAH</last_name>
      <phone>+33 (0)4 91 22 30 68</phone>
      <email>bouabdallahr@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Saint-Eloi</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guillaume CARTRON, MD</last_name>
      <phone>+33(0)4 67 33 83 62</phone>
      <email>guillaume.cartron@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes - Hôtel Dieu</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Legouill, Pr</last_name>
      <phone>+33 (0)2 40 08 30 13</phone>
      <email>steven.legouill@chu-nantes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Necker</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Sibon, MD</last_name>
      <phone>+33 (0)1 44 49 52 86</phone>
      <email>david.sibon@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohamad MOHTY, Pr</last_name>
      <phone>+33 (0)1 49 28 26 20</phone>
      <email>mohamad.mohty@inserm.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>APHP - Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Thieblemont, MD</last_name>
      <phone>+33 (0) 1 42 49 98 37</phone>
      <email>catherine.thieblemont@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital La Pitié Salpétriere</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sylvain Choquet</last_name>
      <phone>+33 (0)1 42 16 28 26</phone>
      <email>sylvain.choquet@aphp.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Francois Magendie</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kamal BOUABDALLAH</last_name>
      <phone>+33 (0)5 57 65 65 11</phone>
      <email>kamal.bouabdallah@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Kamal BOUABDALLAH, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles SALLES, MD</last_name>
      <phone>+33 (0)4 78 86 43 40</phone>
      <email>gilles.salles@chu-lyon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Robert Debré</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain DELMER, Pr</last_name>
      <phone>+33 (0)3 26 78 36 44</phone>
      <email>adelmer@chu-reims.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes - Hôpital Pontchaillou</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry LAMY-DE-LA-CHAPELLE, MD</last_name>
      <phone>+33 (0)2 99 28 42 91</phone>
      <email>thierry.lamy.de.la.chapelle@chu-rennes.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hervé TILLY</last_name>
      <phone>+33 (0)2 32 08 22 23</phone>
      <email>herve.tilly@chb.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer - Oncopole Toulouse (IUCT-O)</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucie Oberic, Dr</last_name>
      <phone>+33 (0)5 61 77 76 66</phone>
      <email>oberic.l@chu-toulouse.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Brabois</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre FEUGIER</last_name>
      <phone>+33 (0)3 83 15 32 57</phone>
      <email>p.feugier@chru-nancy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy Cancer Campus</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Ribrag, Dr</last_name>
      <phone>+33 (0)1 42 11 45 07</phone>
      <email>vincent.ribrag@gustaveroussy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 27, 2020</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 31, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

